PV Bulletin

Key Considerations for the Development and Use of Digitally Derived Measures for Clinical Investigations

The FDA published joint guidance on the use of Digital Health Technologies (DHTs) for obtaining clinically relevant outcomes in investigations.

Primary source: Download PDF

PV Impact Brief

Urgency: HighConfidence: high

What changed

The FDA has introduced new requirements for the verification and validation of Digital Health Technologies used to generate Digitally Derived Measures (DDMs) in clinical investigations.

Why it matters

These guidelines standardize the collection of safety and efficacy data, facilitating continuous and real-time monitoring of adverse events, and improving the reliability of clinical outcomes derived from DHTs.

Action needed

Clinical investigations must now include justification for DDM selection and ensure that DHTs are verified and validated to support their intended clinical role.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
White Paper
Policy status
new
Publication date
2026-08-20
Policy change
A joint white paper from CDER, CBER, and CDRH on the use of digitally derived measures (DDMs) as clinical outcomes. It emphasizes ensuring these measures are fit-for-purpose and supported by evidence for use in clinical investigations.

Key changes

Framework for using digital health technologies (DHTs) to capture clinical outcomes; emphasis on clinical relevance and evidence requirements.

Affected workflows

Signal Management

Responsible groups

Clinical SafetyDigital Health TeamPV Operations

PV impact

Standardizes the use of digital tools for safety and efficacy endpoint collection in clinical trials. This facilitates continuous and real-time monitoring of adverse events and improves the reliability of safety data captured via DHTs.

View regulator source

Source document details

Exact policy details

Digital Health Technologies and DDMs Definition
Measures derived from data collected using DHTs
Applies to: Medical devices developing clinically relevant outcome measures
This paper refers to measures derived from data collected using DHTs as digitally derived measures (DDMs). · p. 1 · High · Source
DDM Verification Requirement
A DHT used to generate a DDM should be verified and validated to be considered fit for purpose.
Applies to: Clinical investigations utilizing DDMs
In the context of clinical investigations, a DHT used to generate a DDM should be verified and validated to be considered fit for purpose. · p. 8 · High · Source
Meaningfulness of DDMs
Encourages assessment of clinical outcomes that are clinically relevant and meaningful to patients
Applies to: Developers of DDMs for clinical investigations
FDA encourages the assessment of clinical outcomes that are both clinically relevant and capture what is meaningful to patients. · p. 3 · High · Source
Justification for DDM
Start with a justification that may be updated over time for DDM selection, relevance, and validity
Applies to: Clinical investigations involving DDMs
When considering incorporating a DDM as an outcome in a clinical investigation, it can be helpful to start with a justification, which may be updated over time. · p. 3 · High · Source
Validation Steps for DDMs
Validation consists of analytical validation and clinical validation
Applies to: Developers and sponsors involved in DDM creation
Validation of a DDM consists of two major parts – analytical validation and clinical validation. · p. 8 · High · Source

Workflow rule impacts

Country ComplianceRegulatory Affairs

May require updates to regulatory submissions and oversight due to new DDM definitions.

Need to incorporate DDMs into compliance frameworks for medical devices.

The paper outlines a framework for the incorporation of DDMs in clinical investigations. · p. 4 · High · Source

Extracted documents

Unable to extract linked source document: https://www.hhs.gov/vulnerability-disclosure-policy/index.html

Evidence and confidence

Confidence: highSource updated: Aug 20, 2026

Full briefing

Practical implication

Clinical investigations must now include justification for DDM selection and ensure that DHTs are verified and validated to support their intended clinical role.

The FDA's joint paper emphasizes the importance of digitally derived measures (DDMs) in clinical investigations, ensuring they are evidence-based and fit for purpose. Key aspects include verification and validation requirements of DHTs and a focus on the meaningfulness of outcomes to patients, which influences safe and effective medical product development.

What changed: The FDA has introduced new requirements for the verification and validation of Digital Health Technologies used to generate Digitally Derived Measures (DDMs) in clinical investigations.

Why it matters: These guidelines standardize the collection of safety and efficacy data, facilitating continuous and real-time monitoring of adverse events, and improving the reliability of clinical outcomes derived from DHTs.

Practical implication: Clinical investigations must now include justification for DDM selection and ensure that DHTs are verified and validated to support their intended clinical role.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward